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Background. Drug treatment is becoming more expensive due to the increased cost for the introduction of new drugs, and
there seems to be an uneven distribution of medication cost for different therapeutic categories. We hypothesized that the
cost of new antimicrobial agents may differ from that of other therapeutic categories and this may play a role in the stagnation
of development of new antibiotics. Methodology/Principal Findings. We performed a pharmaco-economical comparative
analysis of the drug cost of treatment for new agents introduced in the United States drug market in various therapeutic
categories. We calculated the drug cost (in US dollars) of a ten-day treatment of all new drugs approved by the FDA during the
period between January 1997 and July 2003, according to the 2004 Red Book Pharmacy’s Fundamental Reference. New anti-
neoplastic agents were found to be the most expensive drugs in comparison to all other therapeutic categories, with a median
ten-day drug-treatment cost of US$848 compared to the median ten-day drug-treatment costs of all other categories ranging
from US$29 to US$301. On the other hand, new antimicrobial drugs were found to be much less expensive, with a median ten-
day drug-treatment cost of US$137 and $US85 for all anti-microbial agents and for anti-microbial agents excluding anti-HIV
medications, respectively. Conclusions/Significance. The drug-treatment cost of new medications varies considerably by
different therapeutic categories. This fact may influence industry decisions regarding the development of new drugs and may
play a role in the shortage of new antimicrobial agents in the fight against the serious problem of antimicrobial resistance.
Citation: Falagas ME, Fragoulis KN, Karydis I (2006) A Comparative Study on the Cost of New Antibiotics and Drugs of Other Therapeutic
Categories. PLoS ONE 1(1): e11. doi:10.1371/journal.pone.0000011
INTRODUCTION
The investment of societies around the world on biomedical
research leads to important developments including the continu-
ous discovery of new pharmaceutical compounds. It is not clear,
however, whether newly developed and approved drugs cover all
therapeutic areas in a relatively uniform manner. Different reasons
might be postulated with respect to the driving forces of drug
development [1].
Some may argue that more drugs are being developed in areas
where the benefits to the society are maximized whereas others
may claim that the direction is led to where the economic incentive
for the pharmaceutical industry is higher [2–5]. A third reason
may be a mounting social pressure from rising prevalence and
incidence of certain health problems. Other reasons, which may
influence drug development, may include the failure of current
medications to solve existing health problems or the identification
of new diseases such as the highlighted example of AIDS. The
problem of new drugs–usually more expensive - substituting for
older ones with similar chemical structure, which are loosing
patent privileges, is thought to be one of the factors contributing to
the increasing annual drug expenditure around the world.
The problem of shortage of new anti-microbial agents has been
well described in the medical literature [6]. This disturbing fact is
occurring despite the gradually increasing prevalence of microbial
resistance to existing antibiotics in various parts of the word [7–9].
A significant reduction (56%) of new approvals of antibacterial
agents occurred during the period 1998–2002 compared to the
period 1983–1987. In addition, the fact that only 6 out of 506
drugs disclosed in the development programs of the largest
pharmaceutical and biotechnology companies are antibacterial
agents is really distressing [10].
We hypothesized that the cost of new antimicrobial agents
compared to new medications in other therapeutic areas may be
a reason that plays a significant role in the relatively stagnated
market of new anti-microbial agents, especially for non-HIV
infectious diseases. Thus, we performed a pharmaco-economical
study in order to analyze the cost of newly approved drugs and
compare the overall treatment cost for new drugs between
different therapeutic categories.
METHODS
For the purpose of our study we analyzed data regarding original
new drugs applications approved by the U.S. Food and Drug
Administration (FDA) from January 1997 to July 2003. The data
were obtained from the FDA website [11]. Based on the FDA
definition of original new drugs, compounds that have the same
chemical structure with an already approved medication are not
considered new drugs.
In order to conduct our analysis, we classified each new drug in
one of sixteen main therapeutic categories. However, four
therapeutic categories were excluded from further analysis because
of the small number of new drugs developed in each category. The
excluded categories were: contrast agents [including 3 new drugs
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microspheres)], antidotes [including 1 new drug (fomepizole)],
ear, nose and throat drugs [including 1 new drug (cevimeline)],
and anesthesiology drugs (there was no new medication in this
category during the study period). In addition, urea C-14 was not
included in the gastrointestinal category since it is used exclusively
for diagnostic purposes.
The cost of each new drug was determined using the Average
Wholesale Price found in the Red Book Pharmacy’s Fundamental
Reference, 2004 edition [12]. In order to compare the treatment
cost of new drugs for different therapeutic categories, we made
several assumptions. First, we calculated the cost of a ten-day drug-
treatment for each new drug. For drugs that are used for a shorter
period than ten days, we defined as ‘‘ten-day drug-treatment cost’’,
the price of the drug formulation with the fewer possible units of
the medication required for each patient. We then calculated the
median, mean, and the range of the ten-day drug-treatment cost of
new drugs in the defined therapeutic categories.
RESULTS
One hundred and twenty-nine new drugs were approved by the
FDA during the study period (January 1997 to July 2003). In
Table 1 we present 124 new drugs approved, classified in 12
therapeutic categories that we analyzed further. In Table 2 we
present the number of new drugs by therapeutic category as well
as summary data on the drug cost of a ten-day treatment. All drug
prices were presented in 2004 U.S. dollars (USD).
The categories with the most expensive new medications were
the antineoplastic and immunosuppressive agents, the drugs for
the respiratory tract, and the cardiovascular medications. The
median, mean, and range of the drug cost of a ten-day treatment
with new anti-neoplastic agents were 848, 1,455, and 41–4,182
USD respectively. The corresponding numbers for the drug cost of
treatment with new agents involving the respiratory system were
301, 264 and 7–1300 USD, for cardiovascular new agents 184,
969 and 14–7,912 USD, and for new anti-infectious agents 137,
468 and 14–3,682 USD. The median, mean, and range of the
drug cost of a ten-day treatment with new agents used for the
management of the HIV infection were 178, 302, and 105–1,080
USD respectively; the corresponding numbers for non-HIV
antimicrobial agents were 85, 600, and 14–3,682 USD.
DISCUSSION
We studied the drug cost of the treatment of new agents to
examine whether there are any important differences between the
various therapeutic categories. It is interesting that the cost of
treatment of new antineoplastic and immunosuppressive drugs is,
by far, the highest compared to all other therapeutic categories.
The drug-treatment cost of agents from the respiratory system and
cardiovascular system category followed the anti-neoplastic agents
category. The high drug cost, combined with the long duration of
diseases for which most of these agents are prescribed, may explain
the huge sales revenues from these drugs.
The median drug cost of a ten-day treatment of an
antineoplastic agent was actually more than 6 times higher than
the respective value in the category of antimicrobial agents; the
difference is even more pronounced if someone excludes from the
category of new antimicrobials, the drugs for the management of
HIV infection. In fact, anti-neoplastic agents are given in
prolonged cycles of chemotherapy and it is, therefore, reasonable
to assume that our analysis actually underestimated the true drug
cost of treatment for anti-neoplastic agents.
Although, we did not make an attempt to study the differences
in the cost of pre-marketing development of new drugs in different
therapeutic categories, we postulate that the observed differences
in drug-treatment cost, and subsequently the drug sales revenue,
may play a role in the decision making process for the introduction
of new drugs. It may also be one of the factors that has led to
a relative shortage of new antibiotics. It should be emphasized that
the pre-marketing cost of development of new chemical entities
has been found to be higher for anti-infective agents compared to
several other categories of drugs, including cardiovascular and
neuro-pharmacological agents [1].
Table 1. Original new drugs in different therapeutic categories by chronological order of approval from the FDA (January 1997–
July 2003).
..................................................................................................................................................
Anemia, Water, Electrolytes Zoledronic acid, sevelamer, iron sucrose, ferric sodium gluconate, anagrelide
Antineoplastic, Immunosuppressive Imatinib, triptorelin, sirolimus, arsenic trioxide, busulfan, temozolomide, epirubicin, exemestane, bexarotene, capecitabine,
valrubicin, toremifene, letrozole
Cardiovascular Perflutren lipid microsphere, nesiritide, fondaparinux, tinzaparin, telmisartan, bivalirudin, cilostazol, dofetilide, lepirudin,
eptifibatide, tirofiban, candesartan, irbesartan, fenoldopam, clopidrogel, eprosartan
Central Nervous System Galantamine, zolmitriptan, ziprasidone, oxcarbazepine, almotriptan, dexmethylphenidate, frovatriptan, sodium oxybate,
zonisamide, rivastigmine, rizatriptan, zaleplon, entacapone, levetriacetam, citalopram, toclapone, naratriptan, modafinil,
pramipexole, tiagabine, quetiapine, ropinirole, sibutramine
Endocrinology Insulin aspart recombinant, insulin glargine, doxercalciferol, follitropin Alpha/Beta, paracalcitol, repaglinide
Gastrointestinal Esomeprazole, pantoprazole, secretin porcine synthetic, tegaserod, alosetron, balsalazide, orlistat
Gynecology, Urology Drospirenone, ethinyl estradiol, etonogestrel/ethinyl estradiol, dutasteride, cetrorelix, tolterodine, ganirelix, sildenafil,
imiquimod, tamsulosin, raloxifene
Infectious Diseases Valganciclovir, cefditoren, tenofovir, moxifloxacin, lopinavir/ritonavir, efavirenz, voriconazole, doconasol, abanavir/lamivudine/
zidovudine, ritonavir, zanamivir, dalfopristin/quinopristin, oseltamivir, gatifloxacin, rifapentine, nelfinavir, delavirdine,
lamivudine/zidovudine
Musculoskeletal Molexicam, rofecoxib, celecoxib, leflunomide, tiludronate
Ophthalmology Verteporfin, unoprostone, ketotifen, pemirolast, loteprendol, brinzolamide, fomivirsen, emedastine
Respiratory and Allergy Formoterol, desloratadine, levalbuterol, treprostinil, montelukast, guaifenesin, poroctant alpha, nitric oxide
Skin diseases Piperonyl, mequinol/tretinoin, aminolevulinic acid, tazarotene
DOI: 10.1371/journal.pone.0000011.t001
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Cost of New Drugs
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e11Our study has several limitations. First, we had to measure the
drug cost of a defined period of treatment (ten-day treatment) in
order to provide some comparative estimates of treatment cost
with new drugs in different therapeutic categories. The selection of
any time period (e.g. one-day, one-week, one-month, etc) for our
comparative analysis would have its own advantages and
disadvantages given that the duration of treatment differs
considerably for the numerous acute, sub-acute, and chronic
diseases. Second, we calculated only the drug-treatment cost
without taking into consideration other important factors that
influence the cost of medical care, including cost related to the
administration of parenteral medications. Third, we did not take
into account data about the effectiveness and safety of new drugs
in order to perform a comparative assessment of the cost-
effectiveness of new agents in different therapeutic categories.
In addition, we did not examine the reasons for the considerable
differences in the drug-treatment cost of with newly approved
agents. Several factors may contribute to the observed differences in
the cost; including the cost of development, production, and
introduction of new drugsinto the clinicalpractice [13].Specifically,
the cost of the infrastructure necessary for the development of new
drugs may differ for different therapeutic categories. Furthermore,
the cost of clinicaltrials,requiredforthe approvalofnew drugs, may
be also be different for the various therapeutic categories [14,15].
For example, a longer follow up period of observation is necessary
for the determination of the outcome in clinical trials studying anti-
neoplastic compared to antibacterial agents. Moreover, differences
in the failure rate of new drugs to successfully complete phases I to
IV of clinical trials, may contribute to the increased cost of
production of new anti-neoplastic and immunosuppressive drugs.
In conclusion, we found considerable differences in the drug-
treatment cost of new medications between the various therapeutic
categories. It is interesting to note that new drugs used for the
treatment of infections are less expensive, especially if one excludes
new agents for the management of HIV infection. It should be
appreciated that the number of new antimicrobial drugs is actually
quite high despite relatively low ten-day cost. However, this high
number is obviously not sufficient in light of the prevalence/
incidence of infectious diseases and the antimicrobial resistance.
Additional comparative pharmaco-economical studies are needed
to address the question whether new drugs provide good value for
their cost. There is also a need to further explore the differences in
the cost of new agents and the role they play in the relative
stagnation in the development of new antibiotics, in an era when
they are urgently needed because of the pandemic of antimicrobial
resistance.
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